A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

• Status: Recruiting
• Trial end date: 2022-12-14

Summary

A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram negative bacteria.

• Phase: Phase 3

Details

• Lead Sponsor: Pfizer
• Collaborators: Biomedical Advanced Research and Development Authority; Innovative Medicines Initiative (IMI) COMBACTE-CARE (EU)
• Treatments: Avibactam; Aztreonam; Colistin; Meropenem; Metronidazole; Thienamycins